ClinicalTrials.gg
RecruitingNCT00040352Updated Oct 29, 2026

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

An observational study in Melanoma and Dysplastic Nevus Syndrome, sponsored by National Cancer Institute (NCI). Recruiting at 2 sites in United States. Open to participants aged 4 Weeks to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionDysplastic Nevus SyndromeRegistry: MelanomaReclassifiedWhy we changed it
Registry
Melanoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dysplastic Nevus Syndrome
Why
  1. The study's listed conditions name Dysplastic Nevus Syndrome, a narrower term within Melanoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Observational

How we know

From the registry’s dates

  • Started Jul 2002; still recruiting 24 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Other
Enrollment
3,000
Ages
4 Weeks to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Dysplastic Nevus Syndrome with a site in United States — 5 open to participants now, 6 under way, 1 of them phase 3. Dysplastic Nevus Syndrome · United States.

Planned enrollment
Largest of 11
3,000 · median 265
Started
2002
the only one that year
Observational
11 of 17
3 open now
Registered
1st of 17
by date
Lead sponsor
1 of 17
National Cancer Institute (NCI)

Among the 17 studies in Dysplastic Nevus Syndrome with a site in United States, this one has the largest planned enrollment of the 11 observational ones that give a count, is the only one that started in 2002, is one of 11 observational ones, and was the 1st registered.

Dysplastic Nevus Syndrome

24 studies on the registry are indexed under Dysplastic Nevus Syndrome; 7 are open to participants now.

Browse Dysplastic Nevus Syndrome studies →

Open to participants now

5 of the 17 studies in Dysplastic Nevus Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Dysplastic Nevus Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 4 Weeks to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dysplastic Nevus Syndrome with a site in United States, or all of them as a file.
02

Study summary

This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions.

Individuals >=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participants will:

  • Fill out one or two questionnaires about their personal and family medical history.
  • Provide written consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with melanomas, tumors, cancer, or other related illnesses for whom they are the next-of-kin or legally authorized representative.
  • Donate a blood or cheek cell sample to be used for genetic studies. (The blood sample is collected through a needle in an arm vein. The cheek cell sample is obtained either by gently brushing the inside of the mouth with a soft brush or by swishing a tablespoon of mouthwash and then spitting it into a container.)
  • Undergo a skin biopsy (removal of a small piece of skin tissue) for genetic study. For this procedure, the area of skin to be removed is numbed with a local anesthetic and a 1/4-inch piece of skin is excised with a cookie cutter-like instrument. The wound is then covered with a band-aid.

Participants may be asked to travel to the NIH Clinical Center for evaluation, including a medical history, physical examination, and some of the following procedures:

  • Full body skin examination to evaluate the type and number of moles and document any evidence of sun damage to the skin. The examination involves all the skin from the scalp to the bottoms of the feet. After the examination, a medical photographer will photograph the skin, with close-ups of skin lesions marked by the examiner. If there are parts of the skin the participant does not want examined or photographed, he or she can tell the examiner.
  • Blood draw of about 120 milliliters (4 ounces) or less
  • Skin biopsy
  • Cheek cell sample
  • X-rays, ultrasound and magnetic resonance imaging (MRI) studies to detect tumors or changes in tumors or other types of changes in specific tissues. MRI is a diagnostic test that uses strong magnetic fields and radiowaves to examine body tissues. The subject lies on a table that is moved into a large tunnel-like machine (the scanner) for about 45 minutes to 1 hour.

When the tests are finished, a doctor will discuss the results with the participant and the need, if any, for clinical follow-up.

Read the detailed description

Study Description:

Melanoma-prone families and individuals with risk factors for melanoma, including people with Spitzoid tumors and giant congenital nevi, are human models of susceptibility to neoplasia from which mechanisms of cancer susceptibility may be elucidated. For most of the high-risk cancer susceptibility genes, including CDKN2A and CDK4 in melanoma-prone families, germline mutations conferring risk have been found through family studies. Investigations of individuals and families at high risk of melanoma have led to etiologic clues that are important in the general population and have identified persons most likely to benefit from chemoprevention trials and screening programs aimed at early diagnosis of melanoma.

Objectives:

  1. To evaluate and define the clinical spectrum and natural history of disease in syndromes predisposing to melanoma
  2. To evaluate potential precursor states of disease in individuals and families at risk
  3. To quantify risks of melanoma, pancreatic cancer, and other cancers in family members and individuals with an elevated risk for melanoma
  4. To map, clone, and determine function of tumor susceptibility genes in melanoma-prone families, including modifier genes such as pigmentation or dysplastic nevi genes
  5. To identify genetic determinants and gene-environmental interactions conferring melanoma (and other cancer) risk in individuals and families
  6. To evaluate gene-gene and gene-environment interactions in melanoma (and other cancer) formation
  7. To characterize genetic alternations in precursor lesions and melanomas that occur in individuals and families with an increased risk of melanoma.
  8. To educate and counsel study participants about their melanoma risk and methods for primary and secondary prevention of melanoma
  9. To develop educational materials for medical professionals and high-risk family members

Endpoints:

Primary endpoints:

All cancers that occur in individuals and families at high risk of melanoma

Secondary endpoints:

Secondary endpoints are markers of pre-malignant conditions, such as dysplastic nevi, giant congenital nevi, and Spitzoid tumors

03

Conditions studied

  • Melanoma
  • Dysplastic Nevus Syndrome

Browse trials for

Keywords

  • Skin Cancer
  • Risk Factors
  • Melanoma Precursors
  • Genetics
  • Melanoma
04

In context

Dysplastic Nevus Syndrome Reclassified

24 studies on the registry are indexed under Dysplastic Nevus Syndrome; 7 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 283 across 16 observational studies indexed under Dysplastic Nevus Syndrome.

Browse Dysplastic Nevus Syndrome studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Dysplastic Nevus Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Melanoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
4 Weeks to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All members of families with three or more living melanoma cases in the U.S. are eligible for inclusion in the study if the families are willing to participate.@@@@@@

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • On referral, persons >=4 weeks old of any sex, race or ethnicity will be considered for inclusion in the study because of the criteria noted below.
  • Affected: An individual who meets any of the following criteria will be eligible to participate in this study:

    • personal medical history of melanoma of an unusual type, pattern, or number diagnosed at any age; or,
    • known or suspected factor(s) predisposing to melanoma, either genetic or congenital factors (giant congenital nevi, dysplastic nevi, Spitzoid tumors), or unusual demographic features (e.g., very young age of onset, multiple melanomas, previous history of heritable retinoblastoma, Hodgkin's disease, lymphoma, immunodeficiency syndrome, or organ transplant).
    • Ability of the individual or their parent or legal guardian, to understand, and their willingness to provide .
  • Unaffected: An individual who meets any of the following criteria will be eligible to participate in this study:

    • family medical history of melanoma of an unusual type, pattern, or number; or,
    • known or suspected factor(s) predisposing to melanoma, either genetic or congenital factors (giant congenital nevi, dysplastic nevi. Spitzoid tumors), or unusual demographic features (e.g., very young age of onset, multiple melanomas, previous history of heritable retinoblastoma, Hodgkin's disease, lymphoma, immunodeficiency syndrome, or organ transplant).
    • Ability of the individual or their parent, or legal guardian to understand, and their willingness to provide informed consent.
  • Personal and family medical history must be verified through questionnaires, interviews, and review of pathology slides and medical records.

Exclusion criteria

EXCLUSION CRITERIA:

  • Referred individuals and families for whom reported diagnoses cannot be verified;
  • Inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Family-based
Time perspective
Other
Enrollment
3,000 participants (estimated)

Groups and cohorts

  • Affected Individual

    An individual with personal medical history of melanoma of an unusual type, pattern, or number, a known or suspected condition predisposing to melanoma, either genetic or congenital factors (giant congenital nevi, dysplastic nevi, Spitzoid tumors), or unusual demographic features, or any of the other criteria noted in Section 4.1 of the protocol

  • Unaffected individual

    A family member of an affected participant. Family members may include parents, siblings, children or extended family.

07

What researchers measure

Primary outcomes

  1. All cancers that occur in individuals and families at high risk of melanoma

    1\. Identification of major susceptibility genes for melanoma and dysplastic nevi. 2. Prospective risk of melanoma after initial exam and melanoma education. 3. Mortality of melanoma in families. 4. Identification of other risk factors for familial melanoma. 5. Identification of other cancers in melanoma-prone individuals and families.

    Time frame: Ongoing

Secondary outcomes

  1. Secondary endpoints are markers of pre-malignant conditions, such as dysplastic nevi, giant congenital nevi, and Spitzoid tumors

    Identify markers, genes in premalignant conditions.

    Time frame: Ongoing

08

Study locations

2 of 2 sites recruiting
  • National Cancer Institute (NCI)
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office · Contact888-624-1937
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact National Cancer Institute Referral Office · Contact888-624-1937
09

References and documents

Publications

  • Liang X, Pfeiffer RM, Li WQ, Brossard M, Burke LS, Wheeler W, Calista D, Fargnoli MC, Ghiorzo P, Peris K, Bianchi-Scarra G, Chaudru V, Zelenika D, Maeder D, Burdette L, Yeager M, Chanock S, Landi MT, Demenais F, Tucker MA, Goldstein AM, Yang XR. Association of genetic variants in CDK6 and XRCC1 with the risk of dysplastic nevi in melanoma-prone families. J Invest Dermatol. 2014 Feb;134(2):481-487. doi: 10.1038/jid.2013.316. Epub 2013 Jul 26. PubMed 23892592 ↗
  • Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):528-32. doi: 10.1158/1055-9965.EPI-12-1346. PubMed 23549396 ↗
  • Yang XR, Rotunno M, Xiao Y, Ingvar C, Helgadottir H, Pastorino L, van Doorn R, Bennett H, Graham C, Sampson JN, Malasky M, Vogt A, Zhu B, Bianchi-Scarra G, Bruno W, Queirolo P, Fornarini G, Hansson J, Tuominen R, Burdett L, Hicks B, Hutchinson A, Jones K, Yeager M, Chanock SJ, Landi MT, Hoiom V, Olsson H, Gruis N, Ghiorzo P, Tucker MA, Goldstein AM. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. Hum Genet. 2016 Nov;135(11):1241-1249. doi: 10.1007/s00439-016-1715-1. Epub 2016 Jul 23. PubMed 27449771 ↗
  • Sargen MR, Pfeiffer RM, Elder DE, Yang XR, Goldstein AM, Tucker MA. The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of CDKN2A and CDK4. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):676-681. doi: 10.1158/1055-9965.EPI-20-1521. PubMed 33811164 ↗
  • Sargen MR, Pfeiffer RM, Yang XR, Tucker MA, Goldstein AM. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families. J Invest Dermatol. 2020 Jan;140(1):174-181.e3. doi: 10.1016/j.jid.2019.06.138. Epub 2019 Jul 18. PubMed 31326397 ↗
  • Tucker MA, Elder DE, Curry M, Fraser MC, Pichler V, Zametkin D, Yang XR, Goldstein AM. Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades. J Invest Dermatol. 2018 Jul;138(7):1620-1626. doi: 10.1016/j.jid.2018.01.021. Epub 2018 Feb 8. PubMed 29408205 ↗
10

Timeline

5 registry updates since Sep 25, 2026

Started Jul 2002 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2002
First posted
Jun 26, 2002
StartActual
Jul 1, 2002
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description and verification date
5 updates, last Oct 29, 2026
Show all 5 updates
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 26, 2026
    Minor edits only
    + 1 other change: description
  3. Oct 2, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date
  5. Sep 28, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00040352
Responsible party
Sponsor
First posted
Jun 26, 2002
Start date
Jul 1, 2002
Last update
Oct 29, 2026

Study contacts

NCI Family Study Referrals
Contact
ncifamilystudyreferrals@mail.nih.gov
(800) 518-8474
Michael R Sargen, M.D.
Contact
michael.sargen@nih.gov
(240) 276-7354
Michael R Sargen, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion